Baseline differences observed in HBV-TB versus simple HBV patients receiving anti-tuberculosis treatment

This retrospective cohort study evaluated 324 patients, comprising 162 with hepatitis B and tuberculosis co-infection and 162 with simple hepatitis B infection, at a hospital in Huizhou. The analysis focused on baseline characteristics and immune changes, including fluctuations of IFN-gamma, among patients receiving anti-tuberculosis treatment and preventive antiviral treatment. A subgroup of 25 patients underwent specific immunological analysis, while 36 patients were categorized into untreated or treated subgroups for comparison.

Comparative analysis of baseline data indicated that the hepatitis B and tuberculosis co-infection group had a higher proportion of males and elevated levels of white blood cells, neutrophils, monocytes, and platelets relative to the simple hepatitis B infection group. Conversely, levels of HBsAg, HBV DNA, ALT, AST, lymphocytes, and RBC were lower in the co-infection group. The study also noted that baseline data comparison showed these distinct differences between the two populations.

Safety data, adverse events, and tolerability were not reported in the available evidence. The study did not provide specific numerical effect sizes, p-values, or confidence intervals for the observed baseline differences. Limitations regarding the study phase, publication type, and follow-up duration were not reported. Consequently, the observed associations reflect baseline disparities rather than treatment effects, and clinical relevance regarding HBV reactivation or liver injury remains uncertain based on this data alone.